secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001628280-22-021080
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma reports Q2 2022 net loss of $36.3M; cash of $787M funds into 2025
--------------------------------------------------------------------------------

- Revenue of $35.7M (vs $2.6M YoY), driven by $35.3M from concluding GSK hematological cancer research.
- Net loss GAAP $36.3M (vs $62.6M YoY); non-GAAP net loss $10.3M (vs $38.1M YoY).
- R&D expense $43.7M (vs $46.4M YoY); G&A expense $30.5M (vs $19.1M YoY) due to stock compensation.
- Cash, equivalents and marketable securities of $787.0M as of June 30, 2022, providing funding into 2025.
- Lead CAR T candidate LYL797 on track for initial clinical data in 2023; preclinical data presented at ASGCT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022021080/0001628280-22-021080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022021080/lyel-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-021080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer